Goals of this study
1. Determine the sensitivity of primary tumor cells to immune checkpoint blockade in different molecular
myeloma subtypes.
2. Define, characterize and evaluate the therapeutic potency, and selectivity and toxicity of a NEK2 degrader
CRBN-PROTAC-NEK2i.
3. Determine the therapeutic effects of CRBN-PROTAC-NEK2i and optimize combinations with standard
myeloma drugs and immune checkpoint blockade.
4. Apply to the FDA for an Investigational New Drug for the CRBN-PROTAC-NEK2i in collaboration with a
pharmaceutical company for clinical trials in aggressive and relapsed myeloma patients.